| MeSH term | MeSH ID | Detail |
|---|---|---|
| Thalassemia | D013789 | 8 associated lipids |
| Thrombasthenia | D013915 | 4 associated lipids |
| Thrombocytopenia | D013921 | 15 associated lipids |
| Thrombocytosis | D013922 | 4 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Thyroid Neoplasms | D013964 | 33 associated lipids |
| Thyroiditis, Autoimmune | D013967 | 9 associated lipids |
| Toxemia | D014115 | 3 associated lipids |
| Tumor Virus Infections | D014412 | 8 associated lipids |
| Uremia | D014511 | 33 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- J. Lipid Res. (5)
- Proc. Natl. Acad. Sci. U.S.A. (2)
- Am. J. Physiol. Gastrointest. Liver Physiol. (2)
- Others (26)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Nystrom ML et al. | Platelet shape change in whole blood: differential effects of endotoxin. | 1994 | Thromb. Haemost. | pmid:8091394 |
| Tranquille N and Emeis JJ | The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. | 1993 | Thromb. Haemost. | pmid:8097063 |
| Iyú D et al. | The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. | 2012 | Thromb. Haemost. | pmid:22318645 |
| Koyama M et al. | Surface coverage of vascular grafts with cultured human endothelial cells from subcutaneous fat tissue obtained with a biopsy needle. | 1996 | Thromb. Haemost. | pmid:8903004 |
| Selak MA | Neutrophil elastase potentiates cathepsin G-induced platelet activation. | 1992 | Thromb. Haemost. | pmid:1333649 |
| Handley DA et al. | Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. | 1984 | Thromb. Haemost. | pmid:6495262 |
| Taylor RR et al. | Time dependence of whole blood aggregation in response to platelet activating factor (PAF). | 1988 | Thromb. Haemost. | pmid:3388292 |
| Powling MJ and Hardisty RM | Potentiation by adrenaline of Ca2+ influx and mobilization in stimulated human platelets: dissociation from thromboxane generation and aggregation. | 1988 | Thromb. Haemost. | pmid:3388294 |
| Mohanty D and Hilgard P | A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. | 1984 | Thromb. Haemost. | pmid:6740552 |
| Montrucchio G et al. | Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. | 2003 | Thromb. Haemost. | pmid:14597983 |
| Pipili E | Platelet membrane potential: simultaneous measurement of diSC3(5) fluorescence and optical density. | 1985 | Thromb. Haemost. | pmid:2418525 |
| Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
| Kakishita E et al. | Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. | 1990 | Thromb. Res. | pmid:2082481 |
| Powling MJ and Hardisty RM | Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. | 1986 | Thromb. Res. | pmid:3787566 |
| Siffert W et al. | Inhibition of platelet aggregation by amiloride. | 1986 | Thromb. Res. | pmid:3787567 |
| Alam I et al. | Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. | 1983 | Thromb. Res. | pmid:6407140 |
| Simon MF et al. | Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. | 1987 | Thromb. Res. | pmid:3576518 |
| Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
| Alam I and Silver MJ | Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. | 1987 | Thromb. Res. | pmid:3576519 |
| Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
| Ostermann G et al. | Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. | 1983 | Thromb. Res. | pmid:6408754 |
| Vargaftig BB et al. | Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. | 1982 | Thromb. Res. | pmid:7164036 |
| Hanss M and Dechavanne M | 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. | 1988 | Thromb. Res. | pmid:3126559 |
| Okamoto M et al. | Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. | 1986 | Thromb. Res. | pmid:3754990 |
| Bretschneider E et al. | ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. | 1994 | Thromb. Res. | pmid:7992234 |
| Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
| Jones KP et al. | Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. | 1994 | Thromb. Res. | pmid:7992251 |
| Violi F et al. | Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. | 1989 | Thromb. Res. | pmid:2506658 |
| Kurose I et al. | Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. | 1991 | Thromb. Res. | pmid:1650966 |
| Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. | 1987 | Thromb. Res. | pmid:3647677 |
| Valone FH | Platelet-activating factor binding and metabolism during human platelet aggregation. | 1988 | Thromb. Res. | pmid:3400077 |
| Ostermann G et al. | Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. | 1984 | Thromb. Res. | pmid:6710440 |
| Suttorp N et al. | Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. | 1992 | Thromb. Res. | pmid:1440526 |
| Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
| Croft KD and Beilin LJ | Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. | 1993 | Thromb. Res. | pmid:8385810 |
| Vrzheshch PV et al. | Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. | 1992 | Thromb. Res. | pmid:1523610 |
| Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
| Valone FH and Johnson B | Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. | 1985 | Thromb. Res. | pmid:4082115 |
| Kawamura M et al. | Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. | 1993 | Thromb. Res. | pmid:8332959 |
| Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
| Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
| Battistini B et al. | Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. | 1990 | Thromb. Res. | pmid:2278035 |
| Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
| Suzuki K et al. | The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. | 1980 Feb 1-15 | Thromb. Res. | pmid:6966083 |
| Küster LJ and Frölich JC | PAF-induced platelet aggregation and TXB2 formation. | 1989 | Thromb. Res. | pmid:2922704 |
| Neiman J et al. | Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. | 1989 | Thromb. Res. | pmid:2617478 |
| Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
| Avdonin PV et al. | Evidence for the receptor-operated calcium channels in human platelet plasma membrane. | 1987 | Thromb. Res. | pmid:2438805 |
| Lukaszyk A et al. | Does acute experimental pancreatitis affect blood platelet function? | 1989 | Thromb. Res. | pmid:2524119 |
| May JA et al. | Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. | 1997 | Thromb. Res. | pmid:9361371 |